Skip to content

Author

Ronghui Xu

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Upadacitinib Is Associated with the Lowest Risk of Treatment Failure Among Advanced Therapies for Ulcerative Colitis: A Real-World Administrative Claims Study.

BACKGROUND AND AIMS We compared the real-world effectiveness of advanced therapies (AT) in patients with ulcerative colitis (UC). METHODS Using the OptumLabs® Data Warehouse, a nationally representative US administrative claims database, we identified patients with UC initiating infliximab, adalimumab, vedolizumab, u...

M. Hupé, D. Ahuja, Kuan-Hung Yeh et al. · 0 citations
Aug 2026

Cancer Risk with Advanced Therapies in Patients with Inflammatory Bowel Diseases: An Administrative Claims-based Study.

BACKGROUND AND AIMS We conducted a retrospective cohort study comparing the risk of cancer in patients with inflammatory bowel diseases (IBD) initiating advanced therapies (ATs). METHODS Using an administrative claims database (OptumLabs® Data Warehouse), we identified patients with IBD with no prior history of cance...

D. Ahuja, Kuan-Hung Yeh, Soo-kyung Park et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.